it was found that the lower in vivo potency as a centrally acting dopamine agonist of the 6,7-compared with the 5,6-isomer is almost entirely due to the lower brain concentrations achieved after peripheral administration of equimolar doses .
C0006104
brain
C0086045
concentrations